Thursday, March 30, 2023
SciBase Holding announced that they have entered into a collaboration agreement with Schweiger Dermatology group to pilot Nevisense in Freehold, NJ office. Schweiger Dermatology Group is the largest dermatology practise group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut. The agreement will provide Schweiger Dermatology Group’s Freehold, New Jersey practise with Nevisense, the only FDA approved test for early melanoma detection at point-of-care.
In addition to the early detection benefits for patients, the partnership means clinicians at Schweiger Dermatology Group's Freehold and Verona, New Jersey offices will have access to state-of-the-art melanoma detection technology.
The integration of the Nevisense test during routine skin exams in Freehold and Verona, New Jersey offices offers patients the latest technology for the earliest possible detection of melanoma. Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate. Early testing and treatment are critical for improving survival rates. Providing patients with the most advanced technology further supports commitment for the best patient care.
